{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:26:23Z","timestamp":1793049983132,"version":"4.5.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijid.2026.108954","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:19:10Z","timestamp":1783178350000},"page":"108954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cross-neutralization of SARS-CoV-2 BA.3.2.2 lineage by JN.1 mRNA vaccine-induced immunity"],"prefix":"10.1016","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2219-6839","authenticated-orcid":false,"given":"Kei","family":"Miyakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108954_bib0001","unstructured":"World Health Organization Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC). Statement on the antigen composition of COVID-19 vaccines. https:\/\/www.who.int\/news\/item\/15-05-2025-statement-on-the-antigen-composition-of-covid-19-vaccines; 2025 [accessed 20 May 2026]."},{"key":"10.1016\/j.ijid.2026.108954_bib0002","doi-asserted-by":"crossref","unstructured":"Uriu K, Kaku Y, Uwamino Y, Fujiwara H, Saito F, Genotype to Phenotype Japan (G2P-Japan) Consortium, et al. Antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against SARS-CoV-2 omicron subvariants including JN.1, KP.3.1.1, and XEC. Lancet Infect Dis. 2025;25:e61.","DOI":"10.1016\/S1473-3099(24)00810-7"},{"key":"10.1016\/j.ijid.2026.108954_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00658-9","article-title":"Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2","volume":"26","author":"Zhang","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108954_bib0004","doi-asserted-by":"crossref","first-page":"veag016","DOI":"10.1093\/ve\/veag016","article-title":"Identification and genomic characterization of BA.3.2: a highly divergent BA.3-related SARS-CoV-2 lineage from Southern Africa","volume":"12","author":"Dor","year":"2026","journal-title":"Virus Evol"},{"key":"10.1016\/j.ijid.2026.108954_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00772-8","article-title":"Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2","volume":"26","author":"Kaku","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108954_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00690-5","article-title":"Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation","volume":"26","author":"Happle","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108954_bib0007","doi-asserted-by":"crossref","first-page":"eado2817","DOI":"10.1126\/scitranslmed.ado2817","article-title":"AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults","volume":"16","author":"Cai","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijid.2026.108954_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111845","article-title":"Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents","volume":"41","author":"Cao","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.ijid.2026.108954_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00308-1","article-title":"Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1","volume":"25","author":"Guo","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108954_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011868","article-title":"Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding","volume":"19","author":"Jian","year":"2023","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijid.2026.108954_bib0011","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jmcb\/mjaa047","article-title":"Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles","volume":"12","author":"Miyakawa","year":"2020","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.ijid.2026.108954_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127472","article-title":"Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC","volume":"62","author":"Sano","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2026.108954_bib0013","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.1097211","article-title":"Mapping the antigenic and genetic evolution of influenza virus","volume":"305","author":"Smith","year":"2004","journal-title":"Science"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226005898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226005898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:58:52Z","timestamp":1791212332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226005898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":13,"alternative-id":["S1201971226005898"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108954","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cross-neutralization of SARS-CoV-2 BA.3.2.2 lineage by JN.1 mRNA vaccine-induced immunity","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108954"}}